Gainers

• Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings report came out today.
• Maravai LifeSciences (NASDAQ:MRVI) shares increased by 9.19% to $8.43. The company's market cap stands at $1.1 billion. As per the press release, Q3 earnings came out today.
• Erasca (NASDAQ:ERAS) stock increased by 7.31% to $16.0. The company's market cap stands at $5.1 billion.
• ADMA Biologics (NASDAQ:ADMA) stock moved upwards by 6.87% to $11.2. The market value of their outstanding shares is at $2.4 billion. As per the press release, Q3 earnings came out today.
• Nano X Imaging (NASDAQ:NNOX) shares moved upwards by 6.02% to $0.3. The market value of their outstanding shares is at $24.0 million.
• Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 4.38% to $0.08. The company's market cap stands at $2.0 million.

Losers

• GRAIL (NASDAQ:GRAL) shares fell 18.6% to $117.0 during Wednesday's after-market session. The market value of their outstanding shares is at $6.2 billion. As per the news, the Q3 earnings report came out today.
• Arcutis Biotherapeutics (NASDAQ:ARQT) shares declined by 7.85% to $31.38. The company's market cap stands at $4.0 billion. As per the news, the Q3 earnings report came out today.
• Curis (NASDAQ:CRIS) shares decreased by 6.76% to $1.03. The market value of their outstanding shares is at $1.7 million.
• Equillium (NASDAQ:EQ) stock declined by 5.0% to $1.33. The company's market cap stands at $110.4 million.
• Heron Therapeutics (NASDAQ:HRTX) shares declined by 4.89% to $0.28. The company's market cap stands at $54.0 million.
• Cue Biopharma (NASDAQ:CUE) stock decreased by 4.24% to $19.0. The company's market cap stands at $151.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.